Cathal Friel named Executive Chairman, bringing wealth of experience from hVIVO and Amryt Pharma

Businessman Cathal Friel has become executive chairman of Poolbeg Pharma, the same job he had at Open Orphan (now hVivo) as that firm was developed.

Mr Friel, a co-founder and substantial shareholder, was already non-executive chairman of Poolbeg,

As executive chair he will continue to work closely with CEO Jeremy Skillington, the company said.

The move comes as Poolbeg’s wider leadership has been beefed up with hires from Amryt Pharma, another Mr Friel-backed venture that was sold last year for $1.48bn (€1.38bn).

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn

More articles like this

AI-powered drug discovery is changing the future of medicine

The pharmaceutical industry is being revolutionised by AI, transforming drug discovery with faster research and innovative treatments. Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, leveraging a novel clinical model for faster product development.

The Medicine of Tomorrow

Discover how groundbreaking research is revolutionising disease treatment at Monash Institute of Pharmaceutical Sciences. AI, biology, and data converge for life-changing advancements.

Hookipa Pharma advancing bold acquisition plans with Poolbeg Pharma

US-based biopharmaceutical innovator Hookipa Pharma is advancing non-binding discussions to acquire London-based Poolbeg Pharma in an all-share deal. This transformative proposal could reshape the clinical-stage biopharmaceutical landscape, creating a Nasdaq-listed powerhouse focused on next-generation immunotherapies for